Phase 3
Completed N=708
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Source: ClinicalTrials.gov NCT02558374 ↗Enrolled (actual)
708
Serious AEs
2.5%
Results posted
Apr 2018
Primary outcomePrimary: IOP (Intraocular Pressure) — 23.93; 23.89; 22.67; 22.77 mmHg
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY IOP (Intraocular Pressure) |
23.93; 23.89; 22.67; 22.77; 22.17; 22.04 | — |
| SECONDARY Extent of Exposure |
147.4; 167.7 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Diagnosis of open angle glaucoma or ocular hypertension in both eyes
- Post-washout intraocular pressure >20mmHg and 620µm at screening
- Any abnormality preventing reliable applanation tonometry of either eye
- Clinically significant abnormalities in lab tests at screening
- Known hypersensitivity or contraindication to beta-adrenoceptor antagonists
- Clinically significant systemic disease
- Participation in any investigational study within 60 days prior to screening
- Used any systemic medication that could have a substantial effect in intraocular pressure within 30 days prior to screening
- Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control
Data sourced from ClinicalTrials.gov (NCT02558374). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.